Serplulimab is a humanized PD-1 monoclonal antibody, belonging to the class of immune checkpoint inhibitors, mainly used for immunotherapy of various solid tumors. It activates the human immune system to kill cancer cells by blocking the binding of PD-1 and PD-L1/L2, thereby achieving anti-tumor effects.
1. Core role and indications
indication:
Domestically approved for solid tumors with unresectable or metastatic microsatellite instability (MSI-H) or mismatch repair defects (dMMR), such as colorectal cancer and gastric cancer.
Combination chemotherapy is used to treat specific types of cancer such as non-small cell lung cancer (NSCLC) and extensive stage small cell lung cancer (ES-SCLC).
Mechanism of action:
By blocking the PD-1/PD-L1 signaling pathway, the inhibition of T cells by tumor cells is relieved, restoring the immune system's ability to recognize and clear cancer cells.
2. Usage norms and precautions
Usage and dosage: Intravenous infusion is required, and the specific dosage and cycle are determined by the doctor according to the patient's condition and constitution, usually once every 2-3 weeks.
Adverse reactions:
Common side effects include fatigue, rash, thyroid dysfunction, etc;
Serious immune related adverse reactions (such as pneumonia, hepatitis, enteritis) require timely intervention.
Taboos and Caution:
Prohibited for individuals allergic to drug ingredients;
Patients with active autoimmune diseases, organ transplant recipients, etc. need to be carefully assessed for risk.
3. Medical and medication guidance
Strictly follow medical advice: Sullimumab is a prescription drug and should be used under the guidance of an oncologist. Do not adjust the dosage or discontinue the medication on your own.
Pre treatment evaluation: It is necessary to improve the detection of tumor molecular markers (such as MSI/MRI status), liver and kidney function, and immune status checks.
Monitoring during treatment: Regular re examination of blood routine, imaging evaluation of efficacy, and close observation of immune related adverse reactions.
If symptoms such as persistent fever, difficulty breathing, jaundice, etc. occur during treatment, seek medical attention immediately. This medication needs to be obtained through formal medical institutions, and patients should not easily trust information promoted through informal channels.
